Is that why Mesoblast Limited (MESO) dipped in the early morning trading?
Mesoblast Limited (Nasdaq:MESO) shares were plunging -30.07 to $9.45 in the premarket session recently released an update on the clinical trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) caused by infection with COVID-19 following a third interim analysis of the first 180 patients in the trial by the […]
